Ovarian Cancer Diagnostics and Therapeutics Market Size - Share Outlook, Growth Analysis Report and Forecast Trends (2026-2035)

The ovarian cancer diagnostics and therapeutics market was valued at USD 3.14 Billion in 2025. It is poised to grow at a CAGR of 8.40% during the forecast period of 2026-2035, and reach USD 7.03 Billion by 2035. The market growth is driven by rising ovarian cancer incidence, increasing awareness of early detection, advancements in targeted therapies, improved diagnostic technologies, and expanding clinical research and drug development pipelines.

Latest News on the Ovarian Cancer Diagnostics And Therapeutics Market (2026)

• In March 2026, FDA approved relacorilant with chemotherapy for platinum-resistant ovarian cancer, introducing a novel cortisol-targeting mechanism to enhance treatment response and clinical outcomes.
• In February 2025, the World Ovarian Cancer Coalition reported that ovarian cancer ranks eighth globally, with cases projected to exceed 500,000 annually by 2050, increasing the burden.
• In August 2025, researchers developed a machine learning-based blood test detecting early-stage ovarian cancer with around 92% accuracy, improving early diagnosis and screening potential globally.

Key Market Trends and Insights

• By end users, the hospital segment is expected to dominate the market as it accounted for about 65% market share in the historical period.
• By cancer type, the epithelial tumor segment is anticipated to lead the market, representing about 90% market share in the historical period.
• By region, North America is likely to dominate as it accounted for above 35% market share in the historical period.

Market Size and Forecast

• Market Size 2025: USD 3.14 Billion
• Projected Market Size in 2035: USD 7.03 Billion
• CAGR from 2026-2035: 8.40 %

Ovarian Cancer Diagnostics and Therapeutics Market Overview

The market is expanding due to rising incidence rates, increasing awareness of early detection, and advancements in targeted therapies. Growth is supported by improved diagnostic technologies, biomarker research, and personalized treatment approaches. Expanding screening programs, ongoing clinical trials, and strong pharmaceutical pipelines are further driving innovation and improving patient outcomes globally. The market reached a value of approximately USD 3.14 Billion in 2025.

Ovarian Cancer Diagnostics and Therapeutics Market Growth Drivers

Rising Global Disease Burden Boosting the Market Demand

Increasing incidence rates and lack of effective early screening are major factors intensifying disease burden worldwide. These drivers are amplifying demand for improved detection and treatment strategies. For instance, in February 2025, the World Ovarian Cancer Coalition reported ovarian cancer as the eighth most common cancer among women, with cases projected to rise over 55% to nearly 500,000 annually by 2050, alongside substantial mortality and economic impact. This trend is expected to accelerate the adoption of ovarian cancer diagnostics and support sustained market growth.

Growing Regulatory Approvals and Novel Therapies Driving the Market Value

The increasing incidence of treatment-resistant ovarian cancer and growing demand for targeted therapeutic options are accelerating regulatory advancements globally. These drivers are strengthening innovation in oncology drug development. For instance, in March 2026, the FDA approved relacorilant (Lifyorli) in combination with chemotherapy for platinum-resistant ovarian cancer, targeting cortisol signaling to improve chemotherapy response. This development is expected to accelerate the adoption of targeted therapy and improve patient outcomes during the forecast period.

Ovarian Cancer Diagnostics and Therapeutics Market Trends

Key trends shaping the market include advancements in targeted therapies, growing biomarker-based diagnostics, and increasing adoption of personalized treatment approaches globally.

AI-Driven Blood-Based Diagnostics Advancing Market Development

The rising need for early-stage detection and increasing limitations of conventional diagnostic methods are driving innovation in non-invasive technologies. These factors are accelerating the adoption of biomarker-based testing approaches. For instance, in August 2025, researchers developed a machine learning-based blood test analyzing multiple biomarkers, achieving about 92% accuracy overall and 88% for early-stage detection across nearly 400 patient samples. This development is expected to expand adoption of liquid biopsy technologies in the forecast period.

Ovarian Cancer Diagnostics and Therapeutics Market Segmentation

Market Breakup by Offerings

• Diagnostics
• Biopsy
• Blood-Based Testing
• Imaging Techniques Ultrasound CT Scan PET Scan Others
• Others
• Therapeutics
• Chemotherapy
• Immunotherapy
• Hormonal Therapy
• Radiation Therapy
• Others

Market Breakup by Cancer Type

• Epithelial Ovarian Cancer
• Ovarian Germ Cell Tumors
• Others

Market Breakup by End Users

• Hospitals
• Diagnostic Laboratories
• Cancer Research Institutes
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Ovarian Cancer Diagnostics and Therapeutics Market Share

Epithelial Ovarian Cancer Segment Likely to Dominate the Market by Cancer Type

The epithelial tumor segment is expected to dominate the market as it accounted for about 90% share in the historical period. High prevalence, late-stage diagnosis rates, and strong focus on targeted therapies are supporting segment growth. Increasing adoption of advanced ovarian cancer diagnostics is further improving early detection and treatment planning, contributing to sustained demand across healthcare settings globally.

Ovarian Cancer Diagnostics and Therapeutics Market Analysis by Region

North America is expected to dominate the market as it accounted for above 35% share in the historical period. Strong healthcare infrastructure, high awareness levels, and increased screening initiatives are driving regional growth. Continuous advancements in targeted therapy and ongoing clinical research further support improved treatment outcomes and reinforce market expansion across the region.

Leading Players in the Ovarian Cancer Diagnostics and Therapeutics Market

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

AstraZeneca plc

Founded in 1999 and headquartered in Cambridge, United Kingdom, AstraZeneca plc is a global biopharmaceutical company specializing in oncology innovation. Its portfolio includes targeted therapies and biologics for ovarian cancer, including PARP inhibitors and combination treatments. The company advances precision medicine through robust pipelines in targeted therapy.

Boehringer Ingelheim International GmbH

Established in 1885 and headquartered in Ingelheim, Germany, Boehringer Ingelheim is a research-driven pharmaceutical company with expanding oncology capabilities. Its portfolio includes investigational cancer therapies and biologics targeting tumor pathways. The company focuses on innovation in oncology therapeutics through clinical development and strategic collaborations.

Bristol Myers Squibb Company

Founded in 1887 and headquartered in New York, USA, Bristol Myers Squibb Company is a leading biopharmaceutical firm focused on oncology and immunology. Its portfolio includes immunotherapies and combination regimens used in ovarian cancer management. The company drives innovation through checkpoint inhibitors and advanced immunotherapy solutions.

Eli Lilly and Company

Founded in 1876 and headquartered in Indianapolis, Indiana, USA, Eli Lilly and Company is a global pharmaceutical leader with a strong oncology pipeline. Its portfolio includes targeted therapies and clinical-stage treatments addressing ovarian cancer. The company emphasizes innovation in cancer therapeutics through research-driven drug development.

Other key players in the market are Amneal Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., GSK plc, Pfizer Inc., AbbVie Inc., and Siemens Healthineers AG.

Key Questions Answered in the Ovarian Cancer Diagnostics and Therapeutics Market Report

• What was the ovarian cancer diagnostics and therapeutics market value in 2025?
• What is the ovarian cancer diagnostics and therapeutics market forecast outlook for 2026-2035?
• What major factors aid the demand for the ovarian cancer diagnostics and therapeutics market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major ovarian cancer diagnostics and therapeutics market trends?
• Which offering is likely to dominate the market segment?
• Which cancer type is expected to dominate the market segment?
• Which end users is anticipated to dominate the market segment?
• Who are the key players in the ovarian cancer diagnostics and therapeutics market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?